Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Răzvan Cristescu(Merck & Co., Inc., Rahway, NJ, USA (United States)), David R. Kaufman(Gates (United States)), Terrill K. McClanahan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hongchao Lu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xiao Qiao Liu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jennifer H. Yearley(Merck & Co., Inc., Rahway, NJ, USA (United States)), Erin Murphy(Merck & Co., Inc., Rahway, NJ, USA (United States)), Elizabeth R. Plimack(Fox Chase Cancer Center), Nageatte Ibrahim(Merck & Co., Inc., Rahway, NJ, USA (United States)), Joanne E. Tomassini(Merck & Co., Inc., Rahway, NJ, USA (United States)), Patrick A. Ott(Dana-Farber Cancer Institute), Andrea L. Webber(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xinwei Sher(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael Nebozhyn(Merck & Co., Inc., Rahway, NJ, USA (United States)), Andrey Loboda(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jared Lunceford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Andrew Albright(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robin Mogg(Merck & Co., Inc., Rahway, NJ, USA (United States)), Antoni Ribas(University of California, Los Angeles), Chunsheng Zhang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Andrew K. Joe(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mark Ayers(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jonathan D. Cheng(Princeton University), Tanguy Y. Seiwert(Georgetown University)
Cited by 2,324
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k